Teleflex's management announced a significant acquisition and business split, but the market reacted negatively, dropping the shares over 20%. Fourth quarter earnings and 2025 guidance show weak revenue growth and margin leverage, with potential risks from tariffs and poor execution in key areas. The acquisition of BIOTRONIK's vascular intervention business is risky; it expands Teleflex's vascular intervention business, but the end markets aren't growing that fast and the company is a smaller player.
TFX benefits from a diversified product portfolio in the fourth quarter of 2024, with strength in the Surgical and Interventional segments.
Teleflex Incorporated (NYSE:TFX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Lawrence Keusch - VP-IR & Strategy Development Liam Kelly - Chairman, President & CEO Thomas Powell - EVP & CFO John Deren - Corporate VP and Chief Accounting Officer Conference Call Participants Patrick Wood - Morgan Stanley Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Larry Biegelsen - Wells Fargo Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Craig Bijou - Bank of America Michael Polark - Wolfe Research Mike Matson - Needham Operator Good morning, ladies and gentlemen, and welcome to the Teleflex Fourth Quarter 2024 Earnings Conference Call. At this time all participants have been placed in a listen-only mode.
On Thursday, Teleflex Incorporated TFX will pursue a plan to separate into two new, independent, publicly traded companies:
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teleflex (TFX) came out with quarterly earnings of $3.89 per share, beating the Zacks Consensus Estimate of $3.86 per share. This compares to earnings of $3.38 per share a year ago.
Teleflex said on Thursday it would split into two by spinning off its business that makes devices for the urology, and acute care markets as well as its contract manufacturing unit.
Get a deeper insight into the potential performance of Teleflex (TFX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TFX stays on investors' radars due to its performance in the Vascular Access segment and expansion moves.
Teleflex introduces the Arrowg+ard Blue Plus MSB Procedure Kit in the EMEA.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.